4-amino-7-ethyl-5-fluoro-1-isobutyl-2-{2-[5-bis(4-trimethylacetoxybenzyl)-phosphono]furanyl}benzimidazole | 1201836-58-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚酯
• 英文名称: 4-amino-7-ethyl-5-fluoro-1-isobutyl-2-{2-[5-bis(4-trimethylacetoxybenzyl)-phosphono]furanyl}benzimidazole
• 英文别名: [4-[[[5-[4-Amino-7-ethyl-5-fluoro-1-(2-methylpropyl)benzimidazol-2-yl]furan-2-yl]-[[4-(2,2-dimethylpropanoyloxy)phenyl]methoxy]phosphoryl]oxymethyl]phenyl] 2,2-dimethylpropanoate
• CAS: 1201836-58-9
• 化学式: C₄₁H₄₉FN₃O₈P
• 分子量: 761.828
• InChiKey: LGWFAFOOEKLUIY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  8.4
• 重原子数：
  54
• 可旋转键数：
  17
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.39
• 拓扑面积：
  145
• 氢给体数：
  1
• 氢受体数：
  11

反应信息

• 作为产物：
  描述：

  、 4-(羟基甲基)苯基特戊酸酯 在 吡啶 作用下， 以 氯仿 为溶剂， 生成 4-amino-7-ethyl-5-fluoro-1-isobutyl-2-{2-[5-bis(4-trimethylacetoxybenzyl)-phosphono]furanyl}benzimidazole
  参考文献：
  名称：

  Fructose-1,6-bisphosphatase Inhibitors. 2. Design, Synthesis, and Structure−Activity Relationship of a Series of Phosphonic Acid Containing Benzimidazoles that Function as 5′-Adenosinemonophosphate (AMP) Mimics

  摘要：

  Efforts to enhance the inhibitory potency of the initial purine series of fructose-1,6-bisphosphatase (FBPase) inhibitors led to the discovery of it series of benzirniclazole analogues with hurnan FBPase IC50S < 100 nM. I nhibitor 4.4 emerged as a lead compound based on its potent inhibition of hurnan liver FBPase (IC5() = 55 ilM) and significant glucose lowering in nornial fasted rats. Intravenous administration of 4.4 to Zucker diabetic fatty rats led to rapid and robust glucose lowering, thereby providing the first evidence that FBPase inhibitors could improve glycernia in animal models of type 2 diabetes.

  DOI：

  10.1021/jm901420x

文献信息

• Fructose-1,6-bisphosphatase Inhibitors. 2. Design, Synthesis, and Structure−Activity Relationship of a Series of Phosphonic Acid Containing Benzimidazoles that Function as 5′-Adenosinemonophosphate (AMP) Mimics
  作者：Qun Dang、Srinivas Rao Kasibhatla、Wei Xiao、Yan Liu、Jay DaRe、Frank Taplin、K. Raja Reddy、Gerard R. Scarlato、Tony Gibson、Paul D. van Poelje、Scott C. Potter、Mark D. Erion

  DOI：10.1021/jm901420x

  日期：2010.1.14

  Efforts to enhance the inhibitory potency of the initial purine series of fructose-1,6-bisphosphatase (FBPase) inhibitors led to the discovery of it series of benzirniclazole analogues with hurnan FBPase IC50S < 100 nM. I nhibitor 4.4 emerged as a lead compound based on its potent inhibition of hurnan liver FBPase (IC5() = 55 ilM) and significant glucose lowering in nornial fasted rats. Intravenous administration of 4.4 to Zucker diabetic fatty rats led to rapid and robust glucose lowering, thereby providing the first evidence that FBPase inhibitors could improve glycernia in animal models of type 2 diabetes.